# A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel

> **NCT00764166** · PHASE3 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 254 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate

## Interventions

- **DRUG:** Docetaxel + hormonal treatment (LH-RH agonist)
- **DRUG:** Hormonal treatment (LH-RH agonist)

## Key facts

- **NCT ID:** NCT00764166
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2003-06
- **Primary completion:** 2009-11
- **Final completion:** 2010-11
- **Target enrollment:** 254 (ACTUAL)
- **Last updated:** 2008-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00764166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00764166, "A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00764166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*